ACRS Aclaris Therapeutics, Inc.
Company Analysis
Latest News
Aclaris Therapeutics narrower third quarter 2026 loss beat estimates as cash runway extends to 2029
Aclaris Therapeutics reported a narrower-than-expected net loss for the third quarter of 2026, driven by disciplined research spending and a gain from the...
Aclaris Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Aclaris Therapeutics is expected to report a Q3 2026 consensus loss of $0.16 per share on revenue of $5.6 million, with the current $2.12 stock price trading...
Aclaris Therapeutics Announces Underwritten Offering to Raise Approximately $46.7 Million
Aclaris Therapeutics entered into an underwriting agreement for a public offering of common stock and pre-funded warrants. The company expects to raise...
Aclaris Therapeutics Reports $204.6M Cash and Positive Phase 1b ATI-052 Results for Third Quarter 2026
Aclaris Therapeutics announced positive proof-of-concept results from its Phase 1b trials of ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in...
RA Capital Nearly Doubles Stake in Aclaris Therapeutics (ACRS)
Biotechnology investor RA Capital Management significantly increased its holdings in Aclaris Therapeutics during the second quarter of 2026. According to its...